A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)

Shinichiro Okamoto, M. Harada, S. Kato, Y. Morishima, M. Imamura, S. Tsuchiya, Y. Yamada, H. Kodo, Y. Hoshi, M. Tsuchida

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Between January 1993 and June 1994, the JMDP facilitated marrow donations from unrelated donors for 171 patients with malignant and non-malignant disorders. The median age of the patients was 21 years. All patients received marrow from phenotypically HLA -A, -B, -DR identical donors. About half of the patients wrer treated with total body irradiation (TBI)-containing regimens and about 80% of the patients received short-courses methotrexate and cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Eight out of 171 patients, (4.7%) had graft failure and 63 out of 144 patients (44%), who survived for more than 30 days posttransplant, developed grade II to IV acute GVHD. The incidence of chronic GVHD was 47% (extensive form; 27%); most of them were progressive/quiscent type. The incidence of moderate to severe acute GVHD was higher than that observed in sibling transplants. On the other hand, the incidence of chronic GVHD was similar to that observed in sibling transplants. Overall survival at 1.5 years posttransplant was about 50% with no significant differences between diseases. The age correlated significantly with the survival in standard risk leukemia but not in high-risk leukemia. Despite the risk of graft failure and acute GVHD, this preliminary analysis demonstrates that transplantation of marrow from unrelated donors can be an effective treatment for certain hematologic disorders.

Original languageEnglish
Pages (from-to)524-529
Number of pages6
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology
Volume36
Issue number6
Publication statusPublished - 1995 Jun
Externally publishedYes

Fingerprint

Graft vs Host Disease
Japan
Transplantation
Bone Marrow
Tissue Donors
Transplants
Unrelated Donors
Siblings
Incidence
Leukemia
HLA-A Antigens
HLA-B Antigens
Survival
Whole-Body Irradiation
Methotrexate
Cyclosporine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP). / Okamoto, Shinichiro; Harada, M.; Kato, S.; Morishima, Y.; Imamura, M.; Tsuchiya, S.; Yamada, Y.; Kodo, H.; Hoshi, Y.; Tsuchida, M.

In: [Rinsho ketsueki] The Japanese journal of clinical hematology, Vol. 36, No. 6, 06.1995, p. 524-529.

Research output: Contribution to journalArticle

Okamoto, S, Harada, M, Kato, S, Morishima, Y, Imamura, M, Tsuchiya, S, Yamada, Y, Kodo, H, Hoshi, Y & Tsuchida, M 1995, 'A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)', [Rinsho ketsueki] The Japanese journal of clinical hematology, vol. 36, no. 6, pp. 524-529.
Okamoto, Shinichiro ; Harada, M. ; Kato, S. ; Morishima, Y. ; Imamura, M. ; Tsuchiya, S. ; Yamada, Y. ; Kodo, H. ; Hoshi, Y. ; Tsuchida, M. / A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP). In: [Rinsho ketsueki] The Japanese journal of clinical hematology. 1995 ; Vol. 36, No. 6. pp. 524-529.
@article{584bf993f95a4b929a89408b70569cd4,
title = "A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)",
abstract = "Between January 1993 and June 1994, the JMDP facilitated marrow donations from unrelated donors for 171 patients with malignant and non-malignant disorders. The median age of the patients was 21 years. All patients received marrow from phenotypically HLA -A, -B, -DR identical donors. About half of the patients wrer treated with total body irradiation (TBI)-containing regimens and about 80{\%} of the patients received short-courses methotrexate and cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Eight out of 171 patients, (4.7{\%}) had graft failure and 63 out of 144 patients (44{\%}), who survived for more than 30 days posttransplant, developed grade II to IV acute GVHD. The incidence of chronic GVHD was 47{\%} (extensive form; 27{\%}); most of them were progressive/quiscent type. The incidence of moderate to severe acute GVHD was higher than that observed in sibling transplants. On the other hand, the incidence of chronic GVHD was similar to that observed in sibling transplants. Overall survival at 1.5 years posttransplant was about 50{\%} with no significant differences between diseases. The age correlated significantly with the survival in standard risk leukemia but not in high-risk leukemia. Despite the risk of graft failure and acute GVHD, this preliminary analysis demonstrates that transplantation of marrow from unrelated donors can be an effective treatment for certain hematologic disorders.",
author = "Shinichiro Okamoto and M. Harada and S. Kato and Y. Morishima and M. Imamura and S. Tsuchiya and Y. Yamada and H. Kodo and Y. Hoshi and M. Tsuchida",
year = "1995",
month = "6",
language = "English",
volume = "36",
pages = "524--529",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "6",

}

TY - JOUR

T1 - A preliminary analysis of unrelated marrow transplantations facilitated by the Japan Marrow Donor Program (JMDP)

AU - Okamoto, Shinichiro

AU - Harada, M.

AU - Kato, S.

AU - Morishima, Y.

AU - Imamura, M.

AU - Tsuchiya, S.

AU - Yamada, Y.

AU - Kodo, H.

AU - Hoshi, Y.

AU - Tsuchida, M.

PY - 1995/6

Y1 - 1995/6

N2 - Between January 1993 and June 1994, the JMDP facilitated marrow donations from unrelated donors for 171 patients with malignant and non-malignant disorders. The median age of the patients was 21 years. All patients received marrow from phenotypically HLA -A, -B, -DR identical donors. About half of the patients wrer treated with total body irradiation (TBI)-containing regimens and about 80% of the patients received short-courses methotrexate and cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Eight out of 171 patients, (4.7%) had graft failure and 63 out of 144 patients (44%), who survived for more than 30 days posttransplant, developed grade II to IV acute GVHD. The incidence of chronic GVHD was 47% (extensive form; 27%); most of them were progressive/quiscent type. The incidence of moderate to severe acute GVHD was higher than that observed in sibling transplants. On the other hand, the incidence of chronic GVHD was similar to that observed in sibling transplants. Overall survival at 1.5 years posttransplant was about 50% with no significant differences between diseases. The age correlated significantly with the survival in standard risk leukemia but not in high-risk leukemia. Despite the risk of graft failure and acute GVHD, this preliminary analysis demonstrates that transplantation of marrow from unrelated donors can be an effective treatment for certain hematologic disorders.

AB - Between January 1993 and June 1994, the JMDP facilitated marrow donations from unrelated donors for 171 patients with malignant and non-malignant disorders. The median age of the patients was 21 years. All patients received marrow from phenotypically HLA -A, -B, -DR identical donors. About half of the patients wrer treated with total body irradiation (TBI)-containing regimens and about 80% of the patients received short-courses methotrexate and cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Eight out of 171 patients, (4.7%) had graft failure and 63 out of 144 patients (44%), who survived for more than 30 days posttransplant, developed grade II to IV acute GVHD. The incidence of chronic GVHD was 47% (extensive form; 27%); most of them were progressive/quiscent type. The incidence of moderate to severe acute GVHD was higher than that observed in sibling transplants. On the other hand, the incidence of chronic GVHD was similar to that observed in sibling transplants. Overall survival at 1.5 years posttransplant was about 50% with no significant differences between diseases. The age correlated significantly with the survival in standard risk leukemia but not in high-risk leukemia. Despite the risk of graft failure and acute GVHD, this preliminary analysis demonstrates that transplantation of marrow from unrelated donors can be an effective treatment for certain hematologic disorders.

UR - http://www.scopus.com/inward/record.url?scp=0029320387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029320387&partnerID=8YFLogxK

M3 - Article

C2 - 7643445

AN - SCOPUS:0029320387

VL - 36

SP - 524

EP - 529

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 6

ER -